RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.

Abstract excerpt

Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients with cancer harbor RAS mutations, which are typically associated with poor clinical outcomes. Over the past four decades, KRAS has long been considered an undruggable target due to the absence of suitable small-molecule binding sites within its mutant isoforms. However, recent advancements in...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Carcinogenesis
• Drug Resistance, Neoplasm
• Mutation
• Neoplasms
• ras Proteins